Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R/R indolent non-Hodgkin lymphoma (iNHL; 12...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology Jg. 43; H. 33; S. 3573
Hauptverfasser: Neelapu, Sattva S, Chavez, Julio C, Sehgal, Alison R, Epperla, Narendranath, Ulrickson, Matthew L, Bachy, Emmanuel, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Oluwole, Olalekan O, Yakoub-Agha, Ibrahim, Khanal, Rashmi, Rosenblatt, Joseph D, Wulff, Jacob, Shen, Rhine R, Zhang, Wangshu, Poddar, Soumya, Miao, Harry, Nikolajeva, Olga, Jacobson, Caron A
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 20.11.2025
Schlagworte:
Adult
Aged
Aged, 80 and over
Antigens, CD19 - immunology
Biological Products
Female
Follow-Up Studies
Humans
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Lymphoma, Follicular - immunology
Lymphoma, Follicular - mortality
Lymphoma, Follicular - therapy
Lymphoma, Non-Hodgkin - immunology
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - therapy
Male
Middle Aged
Neoplasm Recurrence, Local - therapy
Progression-Free Survival
Receptors, Chimeric Antigen
ISSN:1527-7755, 1527-7755
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R/R indolent non-Hodgkin lymphoma (iNHL; 127 with FL and 31 with marginal zone lymphoma) after a median follow-up of 64.6 months. Patients underwent leukapheresis and received lymphodepleting chemotherapy and axi-cel (2 × 10 CAR T cells/kg). The overall response rate was 90% (75% complete response rate). The median duration of response was 60.4 months, and the median progression-free survival (PFS) was 62.2 months; median time to next treatment and overall survival were not reached (NR). At data cutoff, 55% of patients were alive without requiring subsequent anticancer therapy. Median lymphoma-specific PFS in patients with FL was NR; 34% had progression or death due to lymphoma or study treatment. Notably, after 30 months postinfusion, progression or lymphoma-related deaths were rare. Late-onset toxicities were infrequent and largely unrelated to axi-cel. Durable response and prolonged survival in FL were associated with robust early CAR T-cell expansion and naïve product phenotype. These findings confirm sustained responses and manageable safety with axi-cel in the long term among patients with R/R iNHL and its potential as a curative therapy in FL.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1527-7755
1527-7755
DOI:10.1200/JCO-25-00668